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Abstract
Aims: The well-known limitations of vitamin K antagonists (VKA) led to development of new oral anticoagulants (NOAC) in
non-valvular atrial fibrillation (NVAF). The aim of this meta-analysis was to determine the consistency of treatment effects of
NOAC irrespective of age, comorbidities, or prior VKA exposure.
Methods and Results: All randomized, controlled phase III trials comparing NOAC to VKA up to October 2012 were eligible
provided their results (stroke/systemic embolism (SSE) and major bleeding (MB)) were reported according to age (# or .75
years), renal function, CHADS2 score, presence of diabetes mellitus or heart failure, prior VKA use or previous
cerebrovascular events. Interactions were considered significant at p ,0.05. Three studies (50,578 patients) were included,
respectively evaluating apixaban, rivaroxaban, and dabigatran versus warfarin. A trend towards interaction with heart failure
(p = 0.08) was observed with respect to SSE reduction, this being greater in patients not presenting heart failure (RR = 0.76
[0.67–0.86]) than in those with heart failure (RR = 0.90 [0.78–1.04]); Significant interaction (p = 0.01) with CHADS2 score was
observed, NOAC achieving a greater reduction in bleeding risk in patients with a score of 0–1 (RR 0.67 CI 0.57–0.79) than in
those with a score $2 (RR 0.85 CI 0.74–0.98). Comparison of MB in patients with (RR 0.97 CI 0.79–1.18) and without (RR 0.76
CI 0.65–0.88) diabetes mellitus showed a similar trend (p = 0.06). No other interactions were found. All subgroups derived
benefit from NOA in terms of SSE or MB reduction.
Conclusions: NOAC appeared to be more effective and safer than VKA in reducing SSE or MB irrespective of patient
comorbidities. Thromboembolism risk, evaluated by CHADS2 score and, to a lesser extent, diabetes mellitus modified the
treatment effects of NOAC without complete loss of benefit with respect to MB reduction.
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Introduction
Non-valvular atrial fibrillation (NVAF) is a major cause of
ischemic stroke and systemic embolism and is consequently
characterized by increased mortality and morbidity and higher
costs of medical care [1,2]. Vitamin K antagonists (VKA),
principally warfarin, have proved to be highly effective in
preventing thromboembolic events in patients with paroxysmal,
persistent, or permanent NVAF [3]. In 29 randomized trials
involving more than 28,000 patients, pooled according to meta-
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analytic methods, adjusted-dose warfarin reduced the risk of stroke
by 64% compared to the control and by 37% compared to aspirin,
but at the cost of an increased risk of bleeding [3]. Furthermore,
warfarin was associated with a 26% reduction in all-cause
mortality, compared to no anticoagulation therapy, in random-
ized, controlled trials in patients with NVAF [3].
New oral anticoagulants (NOAC), directly inhibiting thrombin
or factor Xa, have recently been developed. Their wide
therapeutic windows allow the use of fixed doses without any
need for laboratory monitoring [4,5]. These new drugs could
potentially overcome the well-known limitations of VKA, such as
slow onset of action, need for regular blood sampling to monitor
the international normalized ratio (INR), narrow therapeutic
windows, marked inter-individual variations in drug metabolism,
and multiple drug-drug and drug-food interactions, all of which
lead to an increased risk of bleeding [6,7,8]. NOAC are associated
with a reduced risk of stroke and systemic embolism as well as
major bleeding, especially intracranial bleeding [9,10,11].
However, certain characteristics of patients with NVAF may
modify the treatment effects of NOAC [12]. Post hoc analyses of
Figure 1. Flow chart for trial selection.
doi:10.1371/journal.pone.0091398.g001
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trial data suggest that VKA-naı¨ve patients have a different
response when first treated with warfarin compared to those
previously exposed to VKA, manifested by an increase in major
bleeding [13,14,15]. Moreover, an age .75 years, comorbidities
such as congestive heart failure, hypertension, diabetes mellitus,
and previous stroke or transient ischemic attack, independently
predict thromboembolism and are included in the CHADS2 score,
the most reliably validated index for discriminating patients at
higher risk of stroke [16]. Several of these factors, namely
advanced age, previous stroke and hypertension, are also
associated with a risk of bleeding, as assessed by the HAS-BLED
score [17,18]. These comorbidities consequently affect the
incidence of thromboembolic or bleeding events, or both, and
may modify the benefits and harms of NOAC. Apart from the
interrelationship between risk factors for stroke and bleeding, and
the issue of VKA status (prior exposure or no prior exposure), the
interpretation of subgroup analyses corresponding to these
comorbidities is hampered in published trials by the small number
of outcome events within each subgroup and the lack of power to
detect interactions. At the same time, the multiple interaction tests
performed in each trial engendered a risk of type 1 error, i.e. a
false positive conclusion in favor of superiority of the treatment
investigated over the comparator. The aim of the present meta-
analysis was to evaluate the consistency of the reductions in stroke
and bleeding risks in patients with NVAF irrespective of their
comorbidities and VKA status.
Methods
Inclusion criteria
The meta-analysis was performed according to a prospectively
developed protocol (available from the corresponding author on
request), which pre-specified the research objective, search
strategy, study eligibility criteria, and methods of data extraction
and statistical analysis. All subgroup variables were defined before
the analyses.
Studies were eligible for inclusion in the present meta-analysis if
they were randomized, controlled trials conducted in patients with
NVAF and reported results according to CHADS2 score, age,
presence of heart failure and diabetes mellitus, estimated
glomerular filtration rate, prior exposure to VKA, and previous
stroke or transient ischemic attack (TIA). Patients in the control
group had to have received VKA and patients in the treated group
had to have received an oral Factor Xa or thrombin inhibitor.
Double-blind and open-label trial designs with or without blinded
outcome evaluation were eligible.
Data sources and searches
Medline (PubMed) and Embase were searched up to October
2012 using sensitive methods and employing the key words
rivaroxaban, apixaban, betrixaban, edoxaban (DU-176b), eribax-
aban, ximelagatran, dabigatran, LY 517717, darexaban (YM150),
letaxaban, AZD0837, TTP889, RB006, MCC977 and TAK442
[19,20]. Search terms included combinations of free text and
medical subject headings (MeSH or Emtree). The complete search
strategies may be requested from the authors. The references cited
by the studies, reviews and meta-analyses retrieved by searching
PubMed and Embase were also examined. Unpublished and
ongoing trials were sought in clinical trial registers, including those
of the National Institute of Health, the National Research
Register, Current Controlled Trials, Meta-Embol and Trials
Central. We also searched the Internet using the keywords listed
above, including websites dedicated to the dissemination of clinical
trial results, such as TheHeart.org, and the websites of the
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European Medicines Agency and the US Food and Drug
Administration.
Unpublished studies were included in the meta-analysis if their
design had been previously published in detail and patient
characteristics, follow-up and the main results had been presented
at international congresses. No restrictions concerning non-
English language or small population size were applied. All
qualifying studies were assessed for adequate blinding of random-
ization, completeness of follow-up, and objectivity of the outcome
assessment. Phase II trials and studies with short-term follow-ups
(,12 weeks) were excluded.
Outcomes
The primary efficacy endpoint was the composite of stroke and
systemic embolism. The primary safety endpoint was major
bleeding (including both intracranial and extracranial bleeding), as
defined by International Society on Thrombosis and Haemostasis
[21].
Data extraction
Studies were selected and data extracted by two reviewers (JCL
and CC) independently. The risk of bias was assessed by the
Cochrane Collaboration’s tool. The hazard ratio (or the relative
risk) and its confidence interval were extracted for all subgroups
and directly included in the pooled results [22]. Data regarding
inclusion criteria, events by subgroup and treatment were
abstracted for each individual study or post hoc analysis. The
results obtained on the intention-to-treat population were used for
the main efficacy analyses. The risk of bias was assessed by the
Cochrane Collaboration’s tool [23]. Disagreements were resolved
by a third reviewer. If a trial compared two NOAC treatments to
the reference treatment (VKA), the number of patients in the
reference arm was divided by two so that each patient was
included in the meta-analysis only once.
Statistical analysis
The relative risks (RR) or hazard ratios were weighted by the
inverse of their variance and combined using the logarithm of RR
method according to fixed-effect and random-effect models by R
[24,25]. Interaction was systematically tested for all subgroups and
was considered as significant at p ,0.05. The statistical
heterogeneity between studies was assessed using Cochran’s x2
and I2 tests with a threshold of 0.10 [26]. In the event of
heterogeneity, the results were pooled according to a random-
effect model. Results were presented graphically, including the RR
and corresponding 95% confidence intervals (95% CI).
Results
Literature search and study selection
We identified 1170 references through electronic searches and
17 references by manual searches and contact with experts
(Figure 1). Among these, three studies (including 50,578 patients)
were eligible for analysis [9,10,11], the results of which were
reported in 11 publications in peer-reviewed journals, one
international congress abstract, and one Food and Drug Admin-
istration (FDA) report [27,28,29,30,31,32,33,34,35,36]. Patient
characteristics, study designs and methodological features are
shown in Table 1. Patient inclusion criteria were based on various
combinations of the known risk factors for thromboembolism
included in the CHADS2 score and consequently the proportion of
patients with a CHADS2 score ,2 differed greatly from study to
study, ranging from 0 to 34%. The proportion of VKA-naı¨ve
patients varied from 37% to 50%. The risk of bias according to the
Cochrane Collaboration’s tool mainly reflected the high quality of
the trials included (Table 2). One prospective, randomized, open
trial with a blind evaluation was included (Tables 1 and 2).
Randomization was performed according to a computer-generat-
ed and centralized interactive voice-response system in all trials.
One study stratified patients according to their prior VKA
exposure and site of enrollment. In view of the few studies
included, the source of heterogeneity was not explored.
Direct thrombin inhibitors were assessed in one study and direct
factor Xa inhibitors in two studies (Table 1). Two trials used a
reduced dose of the NOAC in patients with renal failure (apixaban
2.5 mg bid and rivaroxaban 15 mg, respectively) [9,10,37]. All
studies used adjusted-dose warfarin (target INR, 2.0 to 3.0) as the
comparator. The proportion of time during which the INR was in
the therapeutic range ranged from 55% to 64% (Table 1). Renal
function (GFR) was estimated by the Cockcroft-Gault method in
all studies. The data according to subgroup are presented in the
Table 3.
Stroke/systemic embolism and major bleeding risk
reduction
Age and renal insufficiency. Treatment benefit with regard
to SSE risk reduction favored NOAC compared to VKA in both
patients aged over 75 years and younger patients (Figures 2 and 3).
The benefit remained in favor of NOAC with regard to major
bleeding, even though the reduction in risk was lower in elderly
patients (RR=0.86 [0.65–1.14]) than in younger patients
(RR=0.73 [0.64–0.83], p interaction= 0.30) (Figures 2 and 4).
Similar results were observed in patients with normal renal
function and those with moderate or severe renal impairment, the
reductions in SSE and MB being similar in the two subgroups. No
interaction was found between these two subgroups.
Table 2. Assessment of the risk of bias according to the Cochrane Collaboration’s tool.
RE-LY, 2009 + + 2 + + +
ROCKET, 2011 + + + + + +
ARISTOTLE, 2011 + + + + + +
Random
sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
+: Low risk of bias; 2: high risk of bias
doi:10.1371/journal.pone.0091398.t002
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Previous exposure to VKA. NOAC were superior to VKA
irrespective of subgroup, reductions in SSE (Figure S2 and S3) and
MB (Figures 2 and 4) being seen in both VKA-naı¨ve patients
(RR=0.80 [0.70–0.92] and RR=0.84 [0.76–0.94], respectively)
and those previously exposed to VKA (RR=0.83 [0.73–0.94] and
RR=0.78 [0.68–0.91], respectively), with no interaction.
CHADS2 score. The treatment effect of NOAC in terms of
SSE reduction was similar (p = 0.92) irrespective of the CHADS2
score (Figures 2 and 3). The risk of thromboembolism, as defined
by the CHADS2 score, significantly modified the effect of NOAC
on MB reduction (p interaction = 0.01), a greater effect being
evident in patients with CHADS2 scores of 0–1 (RR=0.67 [0.57–
0.79]) than in those with CHADS2 scores $2 (RR=0.85 [0.74–
0.98]) (Figures 2 and 4).
Comorbidities included in the CHADS2 score: heart
failure, prior stroke/transient ischemic attack, and
diabetes mellitus. A trend towards interaction with heart
failure (p = 0.08) was observed with respect to SSE reduction, this
being greater in patients not presenting heart failure (RR=0.76
[0.67–0.86]) than in those with heart failure (RR=0.90 [0.78–
1.04]) (Figures 2 and 3). As regards MB, the test for interaction
showed a non-significant trend (p= 0.06) towards a difference
between patients with (RR=0.97 [0.79–1.18]) and without
(RR=0.76 [0.65–0.88]) diabetes mellitus (Figures 2 and 4). No
interaction was detected for any other comorbidity considered.
Discussion
The goal of this study was to assess the consistency of the
benefit-risk balance of NOAC in patients with NVAF irrespective
Figure 2. Relative risk of stroke and systemic embolism and major bleeding reduction according to age, comorbidities and VKA
status.
doi:10.1371/journal.pone.0091398.g002
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of their characteristics. Overall, our meta-analysis showed a similar
treatment effect of NOAC in almost all the subgroups encountered
in clinical practice, with no qualitative interaction in terms of SSE
or MB reduction, i.e. no reversal of treatment effect leading to an
increase of events with NOAC compared to warfarin. However,
there was a significant quantitative interaction, expressed by a
difference in magnitude of the treatment effect according to
subgroup, the effect of NOAC with regard to MB reduction being
smaller in patients with a high risk of SSE (CHADS2 score $2).
There was also a strong trend towards interaction with diabetes
mellitus in patients with a CHADS2 score $2. It is conceivable
that co-prescription of antiplatelet drugs, more frequent in patients
with a CHADS2 score $2 or diabetes mellitus, might explain an
increased incidence of bleeding events but post hoc analysis of the
RE-LY trial did not indicate an interaction with co-administration
of clopidogrel or aspirin in terms of MB [38]. Some authors have
questioned the repercussions of the variable proportion of patients
with a high CHADS2 score across phase III trials [39,40]. In
particular, the population included in the ROCKET-AF trial
differed from those of ARISTOTLE and RE-LY in that it
comprised a higher proportion of patients with comorbidities. In
addition, heart failure may modify the benefit of NOACs with
respect to SEE reduction, but the magnitude of the interaction did
not permit to draw firm conclusions. Our results tend to
corroborate this concern and call for careful interpretation of
indirect comparisons of the results of trials assessing NOAC [40].
In published trials, the safety and efficacy profiles of NOAC
were not worse than those of VKA, irrespective of patient age and
prior exposure to VKA [15,32]. Moreover, all subgroups derived a
significant benefit from these new drugs in terms of reductions in
MB and/or SSE. NOAC reduced major bleeding in all subgroups
at risk of this iatrogenic event, such as those aged $75 years, those
having experienced a stroke in the past, those with a high
CHADS2 score and those presenting renal impairment [18,31].
The two subgroups at greatest risk of NOAC accumulation, i.e.
elderly patients and those with renal failure, both showed a higher
incidence of bleeding and thromboembolic events [41]. However,
both these subgroups nevertheless derived benefit from NOAC in
terms of diminished SSE risk, with no signal indicating an increase
in MB, except in the case of dabigatran 150 mg, which was
associated with a trend towards an increased risk of MB compared
to VKA. In addition, comparison of both dabigratran doses with
warfarin revealed a significant statistical interaction between
treatment and risk of major bleeds in elderly patients [34]. In
patients with renal failure, subgroup analysis showed a heteroge-
neity of treatment effect, related to a relative increase in bleeding
events with dabigatran compared to rivaroxaban and apixaban.
We postulated that the percentage renal clearances of 80%, 33%
and 25% respectively, in the three treatment groups, might have
led to an increased bleeding risk with dabigatran due to drug
accumulation. Overall, the reduction in the rate of SSE observed
with NOAC versus VKA was similar in patients at increased risk
of thromboembolism events, such as those having experienced a
prior TIA/stroke, those presenting diabetes mellitus or heart
failure, and those aged $75 years [42]. The results were same
whether or not the patients had previously been exposed to VKA.
Figure 3. Detailed forest plot of stroke and systemic embolism
according to (A) age, (B) renal function, (C) prior VKA
exposure, (D) CHADS2 score, (E) heart failure, (F) prior stroke
or transient ischemic attack, (G) diabetes mellitus.
doi:10.1371/journal.pone.0091398.g003
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Our study suffers from several limitations. First, it comprised a
meta-analysis of subgroups. However, most of these subgroups
were well defined and included in the stratification scheme for
randomization in each study. As discussed above, it is likely that
the the studies included in this meta-analysis were not powered to
reach significance for many outcomes in subgroups such as those
comprising patients with a CHADS2 score ,2, those having
previously experienced a TIA or stroke or those with a
GFR,50 mL/min, due to the small population sizes. Second,
we found significant heterogeneity for eight subgroups, but
unfortunately, could not analyze its possible causes in view of
the small number of trials included. Heterogeneity was mainly
observed with respect to MB, a composite outcome encompassing
both intracranial and extracranial bleeding. Whereas the disparity
between the effect of NOAC and that of VKA followed the same
trend in all trials with respect to SSE, the results for MB diverged,
the risk of gastrointestinal bleeding being greater with rivaroxaban
and with dabigatran at 150 mg than with VKA [9,11,43]. Besides
the interaction between CHADS2 score and treatment effect, the
intrinsic pharmacodynamic properties of the different drugs, e.g.
their extent of renal excretion, might explain such differences in
the reduction of extracranial bleeding. Finally, we could not
exclude inflation of the type 1 error due to the multiple tests
performed. For this reason, we choose a conservative threshold of
significance (p ,0.05) to limit the risk of false positive results
despite the lack of power of the interaction test [44].
In conclusion, NOAC appear to be more effective and safer
than VKA in reducing SSE or MB irrespective of patient
comorbidities. The risk of thromboembolism, as evaluated by
the CHADS2 score, and to a lesser extent the presence of diabetes
mellitus and heart failure, modified the treatment effect of NOA
without complete loss of benefit in terms of MB reduction. Other
comorbidities, especially moderate renal impairment or prior
VKA use, were not associated with significant differences in
treatment effect with regard to either bleeding or ischemic risk
reduction. Overall, these new drugs were beneficial for all patient
subgroups in the absence of any contraindication.
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